A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Clinical trial NCT03384654 · COMPLETED
Trial details
- NCT number
- NCT03384654
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-14
- Primary completion
- 2022-09-22
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.